Online inquiry

IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8460MR)

This product GTTS-WQ8460MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8460MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1222MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABR-217620
GTTS-WQ11451MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ8680MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ5872MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CIFN
GTTS-WQ5482MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDB-1
GTTS-WQ2490MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ7456MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ3526MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BART
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW